Processing of macromolecular heparin by heparanase.
 F. Gong, P. Jemth, M. Escobar, M. Vlodavsky, J.-P. Li, U. Lindahl
 J. Biol. Chem. 2003, 278, 35152-35158.

Transgenic expression of mammalian heparanase uncovers physiological functions of heparin sulfate in tissue morphogenesis, vascularization and feeding behaviour.
E. Zcharia, S. Metzger, T. Chajeck-Shaul, H. Aingom, M. Elkin, Y. Friedmann, T. Weinstein, J.P.-Li. U. Lindahl, I. Vlodavsky
FASEB J. 2004, 18, 252/263.

Heparanase gene silencing, invasiveness, angiogenesis, and metastasis.
E. Edovitsky, M. Elkin, E. Zcharia, T. Peretz, I. Vlodavsky
J. Natl. Cancer Inst. 2004, 96, 1219-1230.

Undersulfated and glycol-split heparins endowed with antiangiogenic activity.
B. Casu, M. Guerrini, A. Guglieri, A. Naggi, M. Perez, G. Torri, G. Cassinelli, D. Ribatti, P. Carminati, G. Giannini, S. Penco, C. Pisano, M. Belleri, M. Rusnati, M. Presta
J. Med. Chem. 2004, 47, 838-848.

Synthesis and characterization of hexa- and tetrasacchar ide-like mimics from acetobromotriose and acetobromomaltose, obtained by electrochemical reduction on silver.
M. Guerrini, S. Guglieri, R. Santarsiero, E. Vismara
Tetrahedron: Asymmetry 2005, 16, 243-253.

Complex glycosaminoglycans. Profiling substitution pattern by two-dimensional NMR spectroscopy.
M. Guerrini, A. Naggi, S. Guglieri, R. Santarsiero, G. Torri
Anal. Biochem. 2005, 337, 35-47.

Heparanase accelerates wound angiogenesis and wound healing in mouse and rats models.
E. Zcharia, R. Zilka, O. Jacoby-Zeevi, S. Metzger, R. Sarid, A. Naggi, B. Casu, N. Ilan, I. Vlodavsky, R. Abramovitch
FASEB J 2005, 19, 211-221.

In vivo fragmentation of heparan sulfate by heparanase overexpression renders mice resistant to amyloid protein A amyloidosis.
J-P. Li, M. Escobar, F. Gong, X. Zhang, E. Zcharia, S. Metzger, I. Vlodavsky, U. Lindahl
Proc. Natl. Acad. Sci. USA 2005, 102, 6473-6477.

Modulation of the heparanase-inhibiting activity by heparin through selective desulfation, graded N-acetylation, and glycol-splitting.
A. Naggi, B. Casu, M. Perez, G. Torri, G. Cassinelli, S. Penco, C. Pisano, G. Giannini,R. Ishai-Michaeli, I. Vlodavsky
J. Biol. Chem. 2005, 280, 12103-12113.

Heparanase processing: Site-directed mutagenesis, proteolytic cleavage and activation.
G. Abboud-Jarrous, A. Aingom, Z. Rangini-Guetta, R. Atzmon, S. Elgavish, T. Peretz, I. Vlodavsky
J. Biol. Chem. 2005, 280, 13568-13575.

Over-expression of human heparanase renders mice resistant to inflammatory-associated amyloidosis.
J.-P. Li, M.L. Escobar, F. Gong, X. Zhang, E. Zcharia, R. Kilievsky, I. Vlodavsky, U. Lindahl
Proc. Natl. Acad. Sci. USA 2005, 102, 6473-647.

Undersulfated, low-molecular weight glycol-split heparin as an antiangiogenic VFGF antagonist.
C. Pisano, C. Aulicino, L. Vesci, B. Casu, A. Naggi, G. Torri, D. Ribatti, M. Rusnati, M. Presta
Glycobiology 2005, 15, 1C-6C.

Identification and characterization of heparin/heparan sulfate binding domains of the endoglycosidase heparanase.
F. Levy-Adam, G. Abboud-Jarrous, M. Guerrini, D. Beccati, I. Vlodavsky, N. Ilan
J. Biol. Chem. 2005, 280, 20457-20466.

Generation of ”neoheparin” from E. coli capsular polysaccharide.
U. Lindal, J.-P. Li, M. Kusche-Gullberg, M. Salmivirta, S. Alaranta, T. Veromaa, J. Emeis, I. Roberts, C. Trevor, P. Oreste, G. Zoppetti, A. Naggi, G. Torri, B. Casu
J. Med. Chem. 2005, 48, 349-352.

Identification and characterization of heparin/heparan  sulfate binding domains of the endoglycosidase heparanase.
F. Levy-Adams, M. Guerrini, D. Beccati, I. Vlodavsky, N. Ilan
J. Biol. Chem. 2005, 280, 20457-20466.

Structure and active domains of heparin.
B. Casu
In: Chemistry and Biology of heparin and heparan sulfate, 2005
(H.G. Garg, R.J. Linhardt, C.A. Hales, Eds.) Elsevier, Amsterdam, pp. 1-19.

Glycol-splitting as a device for modulating inhibition of growth factors and heparanase.
A. Naggi
In: Chemistry and biology of heparin and heparan sulfate, 2005.
(H.G. Garg, R.J. Linhardt, C.A. Hales, Eds.) Elsevier, Amsterdam, pp. 461-476.

Role of endothelial heparanase in delayed-type hypersensitivity.
E. Edovitsky, E. Lerner, E. Zcharia, I. Vlodavsky, M. Elkin
Blood 2006, 107, 3609-3616.

The impact of heparanase and heparin on cancer metastasis and angiogenesis.
I. Vlodavsky, G. Abboud-Jarrous, M. Elkin, A, Naggi, B. Casu, S. sasiskharan, N. Ilan
Pathophysiol. Haemost. Thromb. 2006, 35, 116-127.

An ELISA method for the detection and quantification of heparanase.
I. Shafat, E. Zcharia, B. Nisman, Y. Nadir, F. Nakhoul, I. Vlodavsky, N. Ilan
Biochem. Biophys. Res. Comm. 2006, 341, 958-963.

Heparin-like synthetic polymers, named RGTA, mimic biological effects of heparin in vitro.
V. Rouet, A. Meddahi-Pellé, H.Q. Miao, I. Vlodavsky, J.P. Caruelle, D. Barrietault
J. Biomed. Mater. Res. 2006, 78, 792-797.

Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis.
N. Ilan, M. Elkin, I. Vlodavsky
J. Biochem. Cell. Biol. 2006, 38, 2018-2039.

Non-anticoagulant heparins and inhibition of cancer.
B. Casu, I. Vlodavsky, R.D. Sanderson
Pathophysiol. Haemost. Thromb. 2008, 36, 195-203.

High-performance liquid chromatography/mass spectrometric studies on the susceptibility of heparin species to cleavage by heparanase.
A. Bisio, A. Mantegazza, E. Urso, A. Naggi, G. Torri, C. Viskov, B. Casu
Semin. Thromb. Hemost. 2007, 33 (5), 488-495.

Heparanase: structure, biological functions, and inhibition by heparin-derived mimetics of separa sulfate.
I. Vlodavsky, N. Ilan, A. Naggi, B. Casu
Curr. Pharmac. Design 2007, 13, 2057-2073.

O-sulfated bacterial polysaccharides with low anticoagulant activity inhibit metastasis.
M. Borgerström, A. Warri, H. Hilesvuo, R. Kanonen, L. Nissinen, M. Philavisto, A. Mariamaki, I. Vlodavsky, A. Naggi, G. Torri, B. Casu, M. Salvimirta, K. Elenius
Semin. Thromb. Hemost. 2007, 33 (5), 547-556.

P-selectin- and heparanase-dependent antimetastatic activity of non-anticoagulant heparins.
H. Holstetter, A. Naggi, G. Torri, R. Ishai-Michaeli, B. Casu, I. Vlodavsky, L. Borsig
FASEB J. 2007, 21, 3662-3672.

Heparanase, heparin and the coagulation system in cancer progression.
I. Vlodavsky, N. Ilan, Y. Nadir, B. Brenner, B.Z. Katz, A. Naggi, G. Torri, B. Casu, S. Sasisekharan
Thromb. Res. 2007, 120, 112-120.

The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy.
Y. Yang, V. McLeod, Y Day, Y.Khotskaya-Sample, G. Shriver, R. Venkataraman, S. Sasisekharan, A. Naggi, G. Torri, B. Casu, I. Vlodavsky
Blood 2007, 110, 2041-2048.

Heparanase enhances syndecan-1 shedding: a novel mechanism for stimulation of tumor growth and metastasis.
Y. Yang, V. McLeod, H.Q. Miao, A. Theus, F. Zhan, J.D. Shaughnessy, J. Sawyer, J.-P. Li,
E. Zhacaria, I. Vlodavsky, R.D. Sanderson
J. Biol. Chem. 2007, 282, 13326-13333.

Transgenic or tumor-induced expression of heparanase upregulates sulfation of heparan sulfate.
M.L. Escobar Galvis, J. Ja, X. Zhang, N. Jastrebova, D. Spillmann, E. Gottfridsson, T.H. van Kuppevelt, E. Zcharia, I. Vlodavsky, J.-P. Li
Nat. Chem. Biol. 2007, 3, 773-778.
 
Minimum FGF2 binding structural requirements of heparin and heparan sulfate oligosaccharides as determined by NMR spectroscopy.
S. Guglieri, H. Hricovíni, R. Raman, L. Polito, G. Torri, B. Casu, R. Sasisekharan, M. Guerrini
Biochemistry 2008, 47, 13862-13869.

Heparanase: one molecule with multiple functions in cancer progression.
I. Vlodavsky, M. Elkin, G. Abboud-Jarrous, F. Levi-Adam, L. Fuchs. I. Shafat, N. Ilan
Connect. Tissue res. 2008, 49, 207-210.

Heparanase augments epidermal growth factor receptor phosphorylation: correlation with head and neck tumor progression.
V. Cohen-Kaplan, I. Doveck, I. Naroditsky, I. Vlodavsky, N. Ilan
Cancer Res. 2008, 68 10077-10085.

Heparanase facilitases cell aggregation and spreading by clustering of cell surface heparan sulfate proteoglycans.
F. Levy-Adam, S. Feld, E. Suss-Toby, I. Vlodavsky. N. Ilan
PLoS One 2008, 3, e2319.

Heparan sulfate and heparanase in cancer: remedy for metastasis?
J.-P. Li
Anticancer Agents Med. Chem. 2008, PMD 18220506.

Electrochemical characterization of 6-iodomaltose, 6’-iodomaltose and 6-iodomaltotriose on silver cathode and their one-pot electrochemical dimerization to new mixed O/C maltotetraose and maltohexaose mimics.
A. Alberti, D. Macciantelli, A. Naggi, E. Urso, G. Torri, E. Vismara
Chemistry 2009, 15, 8005-8014.

Newly generated heparanase knock-out mice unravel co-regulation of heparanase and matrix metalloproteinases.
E. Zcharia, J. Jaia, X. Xang, L. Baraz, U. Lindahl, T. Peretz, I. Vlodavsky, J.-P. Li
PLos One 2009, 4, e5181.

Heparin, heparan sulfate and heparanase in inflammatory reactions.
J.-P. Li, I. Vlodavsky
Thromb. Haemost. 2009, 102, 823-828.

Molecular structure of heparan sulfate from Spalax. Implications of heparanase and hypoxia.
E. Sandwall, S. Bodevin, N.J. Nasser, E. Nevo, A. Avivi, I. Vlodavsky, J.-P. Li
J. Biol. Chem. 2009, 284, 3814-3822.

Structure-function approach identifies a COOH-terminal domain that mediates heparanase signaling.
L. Fux, N. Feibish, V. Cohen-Kaplan, S. Ginsis-Velitski, S. Feld, C. Geffen, I. Vlodavsky, N. Ilan
Cancer Res. 2009, 69, 1758-1767.

Heparanase: busy at the cell surface.
L. Fux, N. Ilan, R.D. Sanderson, I. Vlodavsky
Trends Biochem. Sci. 2009, 34, 511-519.

Heparin-derived heparan sulfate mimics to modulate heparin sulfate-protein interactions in inflammation and cancer.
B. Casu, A. Naggi, G. Torri
Matrix Biol. 2010, 29, 442-452.

Accumulation of Ym1 and formation of intracellular crystalline bodies in alveolar macrophages lacking heparanase.
I. Waem, J. Jia, G. Pejler, E. Zcharia, I. Vlodavsky, J.-P. Li, S. Warnersson
Mol. Immunol. 2010, 47, 1467-1475.

Focus on molecules: heparanase.
Y. Zhang, D.S. Ryan, K.S. Bower, N. Ilan, I. Vlodavsky, G.V. Laurie
Exp. Eye Res. 2010, 91, 476-477.

Tumorigenic and adhesive properties of heparanase.
F. Levy-Adam, N. Ilan, I. Vlodavsky
Semin. Cancer Biol. 2010, 20, 153-160.

Proteoglycans in health and disease: new concepts for heparanase function in tumor progression and metastasis.
U. Barash, V. Cohen-Kaplan, I. Dowek, R.D. Sanderson, N. Ilan, I. Vlodavsky
FEBS J. 2010, 277, 3690-3693.

SST0001, a chemically modified heparin, inhibits myeloma growth and angiogenesis via disruption of the heparanase/syndecan-1 axis.
J.P. Ritchie, V.C. Ramani, Y. Ren, A. Naggi, G. Torri, B. Casu, S. Penco, C. Pisano, P. Carminati, M. Tortoreto, F. Zunino, I. Vlodavsky, R.D. Sanderson, Y. Yang
Clin. Cancer Res. 2011, 17, 1382-1393.

Sulfated hexasaccharides attenuate metastasis by inhibition of P-selectin and heparanase.
L. Borsig, I. Vlodavsky, R. Ishai-Michaeli, G. Torri, E. Vismara
Neoplasia 2011, 13, 45-52.

Heparanase affects secretory granule homostasis of murine mast cells through degrading heparin.
B. Wang, J. Jia, X. Zhang, E. Zharia, I. Vlodavsky, G. Pejler, J.-P. Li
J. Allergy Clin. Immunol. 2011, 128, 1310-1317.

Effect of solvent and counterions upon structure and NMR spin-spin coupling constants in heparin disaccharide.
M. Hricovini
J. Phys. Chem. B 2011, 115, 1503-1511.

Significance of heparanase in cancer and inflammation.
I. Vlodavsky, P. Beckhove, I. Lerner, C. Pisano, A. Meirovitz, N. Ilan, M. Elkin
Cancer Microenviron. 2012, 5, 115-132.

Heparanase, a multifaceted protein involved in cancer.
I. Vlodavsky et al
In: Extracellular Matrix: Pathobiology and Signaling,(N.K. Karamanos, ed.) DeGruyter 2012, pp.833-864.

Characterizing the microstructure of heparin and heparan sulfate using N-sulfoglucosamine 1H and 15N chemical shift analysis.
D. J. Langeslay, C.N. Beecher, A. Naggi, M. Guerrini, G. Torri, C. K. Larive
Anal. Chem. 2013, 85, 1247-1255.

Profiling glycol-split heparins by high-performance liquid chromatography / mass spectrometry analysis and their heparinase-digested oligosaccharides.
A. Alekseeva, B. Casu, G. Torri, S. Pierro, A. Naggi
Anal. Biochem. 2013, 434, 112-122.

Unraveling structural information from complex mixtures utilizing correlation spectroscopy applied to HSQC spectra.
T.R. Rudd, E. Macchi, L. Muzi, M. Ferro, D. Gaudesi, G. Torri, B. Casu, M. Guerrini, E.A. Yates
Anal. Chem 2013, 85, 7487-7493.

Anti-metastatic semi-synthetic sulphated maltotriose C-C linked dimers. Synthesis and characterization.
E. Vismara, E. Coletti, A. Valerio, A. Naggi, E. Urso, G. Torri
Molecules 2013, ….  9912-9930.

Structural features of glycol-split low-molecular weight heparins and their heparin lyase generated fragments.
A. Alekseeva, B. Casu, G. Cassinelli, M. Guerrini, G. Torri, A. Naggi
Anal. Bioanal. Chem. 2013, DOI 10.1007/s-013-7446-4.

Involvement of heparanase in atherosclerosis and other wessel wall pathologies.
I. Vlodavsky, M. Blich, J.-P. Li, R.D. Sanderson, N. Ilan
Matrix Biol. 2013, 32, 241-251.

Characterization of heparanase-induced phosphatidylinositol 3-kinase-AKT activation and its integrin dependence.
A. Riaz, N. Ilan, I. Vlodavsky, S. Johannson
J. Biol. Chem. 2013, 288, 12366-12375.

Antitumor efficiency of the heparanase inhibitor SST0001 alone and in combination with antiangiogenic agents in the treatment of human pediatric sarcoma models.
G. Cassinelli, C. Lanzi, M. Tortoreto, D. Cominetti, G. Petrangogini, E. Favini, N. Zaffaroni, C. Pisano, S. Penco, I. Vlodavsky, F. Zunino
Biochem. Pharmacol. 2013, 85, 1424-1432.

Pathophysiology of heparan sulfate: many diseases, few drugs.
U. Lindahl, L. Kjellén
J. Intern. Med. 2013, 273, 555-571.

Structural features of glycol-split low-molecular weight heparins and their heparin lyase generated fragments.
A. Alekseeva, B. Casu, G. Cassinelli, M. Guerrini, G. Torri, A. Naggi
Anal. Bioanal. Chem. 2013, in press.

Minimal heparin/heparansulfate sequences cleaved by heparanase” J.-p. Li, 12th Symposium on Glycosaminoglycans, Villa Vigoni (Como, Italy) Sept. 22-24, 2005

Biological activities of heparanase” I. Vlodavsky, 12th Symposium on Glycosaminoglycans, Villa Vigoni (Como, Italy) Sept. 22-24, 2005

Strategies for developing heparan sulfate mimics as heparanase inhibitor” B. Casu, 12th Symposium on Glycosaminoglycans, Villa Vigoni (Como, Italy) Sept. 22-24, 2005

The impact of heparanase on cancer progression" I. Vlodavsky. Montebello Conference on Cancer Metastasis (Lillehammer, Norway, June 2005).

Heparin, heparan sulfate and heparanase in the control of cancer metastasis and angiogenesis" XIII Symposium on Glycosaminoglycans (Lake Como, Italy, Sep. 2005).

Heparanase as a target for the development of anti-cancer drugs" I. Vlodavsky. XVII Symposium on Glycoconjugates (Florence,Italy, September, 2005).

Heparanase induces VEGF expression: Correlation with P38 phosphorylation levels and Src activation" Proteoglycans in Signaling  (Stockholm, Sweden, September 2005)

The impact of heparanase on cancer progression" I. Vlodavsky. 3rd Thrombosis & Hemostasis in Cancer (Bergamo, Italy; Oct. 2005).

Regulation and function of heparanase in cancer progression" I. Vlodavsky.  33rd ISOBM meeting (Rhodes, Greece, September 2005).

Heparanase:basic aspects and clinical applications" I. Vlodavsky. 2nd Russel Berrie International Symposium on Diabetes and Atherosclerois (Jerusalem, September 2005).

Heparanase as a target for the development of anti-cancer drugs" I. Vlodavsky. Polymeric Drugs and Drug Conjugates, The Israel Chemical Society (Jerusalem, December 2005)

Structure of heparan sulfate – how regulated does it need to be?” U. Lindahl. 12th Symposium on Glycosaminoglycans, Villa Vigoni (Como, Italy) Sept. 23-25, 2004

Heparanase – too much and too little?” J.-p. Li. Proteoglycans in Signaling, Stockholm (Runö), Sweden, Sept. 7-11, 2005

Disturbed metabolism of heparan sulfate in heparanase transgenic mice” J.-p. Li. 13th Symposium on Glycosaminoglycans, Villa Vigoni (Como, Italy) Sept. 22-24, 2005

Pharmacodynamics of heparin derivatives in melanoma-bearing mice.” C. Pisano. 13th Symposium on Glycosaminoglycans, Villa Vigoni (Como, Italy) Sept. 22-24, 2005.